ABSTRACT
A 65-year-old man, who had been treated with dabigatran for 66 days prior to electrical cardioversion, developed extensive intestinal, renal and cerebral thromboembolism five days after cardioversion. There is limited information available on the treatment of thromboembolism in patients being treated with dabigatran. Routine biochemical monitoring is not available. As is the case for vitamin K antagonists, anticoagulation with dabigatran is not without risks.
Subject(s)
Antithrombins/adverse effects , Benzimidazoles/adverse effects , Thromboembolism/chemically induced , beta-Alanine/analogs & derivatives , Aged , Antithrombins/administration & dosage , Antithrombins/therapeutic use , Benzimidazoles/administration & dosage , Benzimidazoles/therapeutic use , Cerebral Infarction/chemically induced , Dabigatran , Electric Countershock , Humans , Ileus/chemically induced , Kidney Diseases/chemically induced , Male , Risk Factors , Tomography, X-Ray Computed , Vitamin K/antagonists & inhibitors , beta-Alanine/administration & dosage , beta-Alanine/adverse effects , beta-Alanine/therapeutic useABSTRACT
Calcified amorphoeus tumour of the heart (cardiac CAT) is a rare non-neoplastic tumour of the heart. To the best of our knowledge, this is the first case report of cardiac CAT in Scandinavia. The patient was a 55-year-old woman with obesity, hypertension, hyperlipidaemia, a history of smoking, and a family history of ischaemic heart disease. She presented with dyspnoea and near syncope. The tumour was resected, and cytopathology was preformed on its content. Based on the cytopathology, the pathologist concluded that the tumour most likely was cardiac CAT, though a calcified myxoma could not be excluded with certainty.
